Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia

Stock Information for Tonix Pharmaceuticals Holding Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800
Tonix Pharmaceuticals Posted Results from Pharmacokinetic Analyses of TNX-102 SL and TNX-601 CR in Advance of Virtual Poster Presentations at the American Society of Clinical Psychopharmacology
Tonix Pharmaceuticals Announces Appointment of Herbert Harris, M.D., Ph.D., as Executive Vice President, Translational Medicine
Tonix Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights
Tonix Pharmaceuticals Enters into Research Collaboration and Exclusive License Agreement with University of Alberta to Develop Novel Horsepox-Based Vaccines, TNX-1810, TNX-1820 and TNX-1830, for the Prevention of COVID-19
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia
Tonix Pharmaceuticals to Deliver Virtual Presentation and Participate in Panel Discussion for Planet MicroCap Showcase Virtual Investor Conference 2020
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.